RedHill Biopharma Ltd.
RDHL
$1.02
-$0.01-0.97%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 58.59% | 58.59% | 382.03% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 58.59% | 58.59% | 382.03% |
| Cost of Revenue | -- | -- | 14.46% | 14.46% | -- |
| Gross Profit | -- | -- | 111.64% | 111.64% | -- |
| SG&A Expenses | -- | -- | -34.29% | -34.29% | 61.22% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -- | -23.26% | -23.26% | 30.76% |
| Operating Income | -- | -- | 48.18% | 48.18% | -46.90% |
| Income Before Tax | -- | -- | -33.84% | -33.84% | 110.79% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -- | -- | -33.84% | -33.84% | 110.79% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | -33.84% | -33.84% | 80.88% |
| EBIT | -- | -- | 48.18% | 48.18% | -46.90% |
| EBITDA | -- | -- | 47.57% | 47.57% | -54.35% |
| EPS Basic | 43.56% | 44.18% | 12.70% | 12.70% | 97.51% |
| Normalized Basic EPS | -- | -- | 12.70% | 12.70% | -77.01% |
| EPS Diluted | 43.56% | 44.18% | 12.70% | 12.70% | 97.51% |
| Normalized Diluted EPS | -- | -- | 12.70% | 12.70% | -77.01% |
| Average Basic Shares Outstanding | 156.37% | -- | 53.32% | 53.32% | 375.61% |
| Average Diluted Shares Outstanding | 200.00% | 0.00% | 0.00% | 0.00% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |